Clinical findings before a prescription.
The AUA diagnostic-support cutoff is total testosterone below 300 ng/dL. That value is not a standalone diagnosis or an optimal target. Compatible clinical findings and repeat morning measurements matter.
SHBG helps explain total versus free testosterone context. LH and FSH may help evaluate the hormone pathway. Appropriate follow-up can also include safety and metabolic markers; the test selection is individualized.
TRT can reduce sperm production, so fertility plans belong in the conversation before treatment. A higher laboratory value alone does not establish a clinical benefit.
Not individual medical advice, a patient case or a promised treatment outcome. Treatment suitability requires an individual licensed-provider evaluation.
